TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial - 03/03/20
, Mette Yilmaz, MD d, Sören Möller, PhD b, c, Daniela Zitnjak, PhD e, Merete Krogh, PhD a, Lone Nørgård Petersen, PhD f, Laurids Østergaard Poulsen, PhD d, Stine Braendegaard Winther, PhD a, Karina Gravgaard Thomsen, PhD a, Camilla Qvortrup, PhD fSummary |
Background |
TAS-102 (trifluridine–tipiracil) has shown a significant overall survival benefit compared with placebo in patients with chemorefractory metastatic colorectal cancer. Inspired by the encouraging results of a small phase 1–2 study, C-TASK FORCE, which evaluated the combination of TAS-102 plus bevacizumab in patients with chemorefractory metastatic colorectal cancer, we aimed to compare the efficacy of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients receiving refractory therapy for metastatic colorectal cancer .
Methods |
This investigator-initiated, open-label, randomised, phase 2 study enrolled patients (aged ≥18 years) with metastatic colorectal from four cancer centres in Denmark. The main inclusion criteria were histopathologically confirmed metastatic colorectal cancer refractory or intolerant to a fluoropyrimidine, irinotecan, oxaliplatin, and cetuximab or panitumumab (only for RAS wild-type), and WHO performance status of 0 or 1. Previous therapy with bevacizumab, aflibercept, ramucirumab, or regorafenib was allowed but not mandatory. Participants were enrolled and randomly assigned (1:1) in block sizes of two, four, or six by a web-based tool to receive oral TAS-102 (35 mg/m2 twice daily on days 1–5 and 8–12 every 28 days) alone or combined with intravenous bevacizumab (5 mg/kg on days 1 and 15) until progression, unacceptable toxicity, or patient decision to withdraw. Treatment assignment was not masked, and randomisation was stratified by institution and RAS mutation status. The primary endpoint was investigator-evaluated progression-free survival. All analyses were based on intention to treat. This trial is registered with EudraCT, 2016–005241–23.
Findings |
From Aug 24, 2017, to Oct 31, 2018, 93 patients were enrolled and randomly assigned to TAS-102 (n=47) or TAS-102 plus bevacizumab (n=46). The clinical cut-off date was Feb 15, 2019, after a median follow-up of 10·0 months (IQR 6·8–14·0). Median progression-free survival was 2·6 months (95% CI 1·6–3·5) in the TAS-102 group versus 4·6 months (3·5–6·5) in the TAS-102 plus bevacizumab group (hazard ratio 0·45 [95% CI 0·29–0·72]; p=0·0015). The most frequent grade 3 or worse adverse event was neutropenia (18 [38%] of 47 in the TAS-102 monotherapy group vs 31 [67%] of 46 in the TAS-102 plus bevacizumab group). Serious adverse events were observed in 21 (45%) patients in the TAS-102 group and 19 (41%) in the TAS-102 plus bevacizumab group. No deaths were deemed treatment related.
Interpretation |
In patients with chemorefractory metastatic colorectal cancer, TAS-102 plus bevacizumab, as compared with TAS-102 monotherapy, was associated with a significant and clinically relevant improvement in progression-free survival with tolerable toxicity. The combination of TAS-102 plus bevacizumab could be a new treatment option for patients with refractory metastatic colorectal cancer and could be a practice-changing development.
Funding |
Servier.
Le texte complet de cet article est disponible en PDF.Plan
Vol 21 - N° 3
P. 412-420 - mars 2020 Retour au numéro
Article précédent
- Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial
- John A Bridgewater, Siân A Pugh, Tom Maishman, Zina Eminton, Jane Mellor, Amy Whitehead, Louise Stanton, Michael Radford, Andrea Corkhill, Gareth O Griffiths, Stephen Falk, Juan W Valle, Derek O’Reilly, Ajith K Siriwardena, Joanne Hornbuckle, Myrddin Rees, Timothy J Iveson, Tamas Hickish, O James Garden, David Cunningham, Timothy S Maughan, John N Primrose, New EPOC investigators, Alaaeldin Shablack, Ann O’Callaghan, (Margaret) Anne Moody, Alex Allen, Alison Brewster, Alison Brown, Astrid Mayer, Brian Davidson, Chan Ton, Charles Wilson, Charles Lowdell, Charlotte Rees, Christopher Baughan, Clare Barlow, Colin Purcell, David Smith, David Tsang, Ewan Brown, Georgina Walker, Hassan Malik, Iain Cameron, Luke Nolan, Marcia Hall, Marjorie Tomlinson, Mark Hill, Mark Peterson, Meg Finch-Jones, Nagappan Kumar, Nariman Karanjia, Nasim Ali, Nigel Heaton, Nua Chan Ton, Paul Ross, Raaj Praseedom, Robert Thomas, Sally Clive, Sarah Slater, Sarah Smith, Satvinder Mudan, Satya Bhattacharya, Sharadah Essapen, Sherif Raouf, Stephen Fenwick, Susan Cleator, Tom Diamond, Vanessa Potter
- Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study
- Eugene Suh, Kayla L Stratton, Wendy M Leisenring, Paul C Nathan, Jennifer S Ford, David R Freyer, Jennifer L McNeer, Wendy Stock, Marilyn Stovall, Kevin R Krull, Charles A Sklar, Joseph P Neglia, Gregory T Armstrong, Kevin C Oeffinger, Leslie L Robison, Tara O Henderson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?